Cargando…

Semantic computational analysis of anticoagulation use in atrial fibrillation from real world data

Atrial fibrillation (AF) is the most common arrhythmia and significantly increases stroke risk. This risk is effectively managed by oral anticoagulation. Recent studies using national registry data indicate increased use of anticoagulation resulting from changes in guidelines and the availability of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bean, Daniel M., Teo, James, Wu, Honghan, Oliveira, Ricardo, Patel, Raj, Bendayan, Rebecca, Shah, Ajay M., Dobson, Richard J. B., Scott, Paul A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876873/ https://www.ncbi.nlm.nih.gov/pubmed/31765395 http://dx.doi.org/10.1371/journal.pone.0225625

Ejemplares similares

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2022)

Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation
por: Gustafson, Whitney L., et al.
Publicado: (2019)

Use of Oral Anticoagulation in a Real‐World Population With Device Detected Atrial Fibrillation
por: Kaplan, Rachel M., et al.
Publicado: (2020)

Anticoagulation in atrial fibrillation
por: Steinberg, Benjamin A, et al.
Publicado: (2014)

Anticoagulation in atrial fibrillation: the present and the future
por: Dweck, Marc R, et al.
Publicado: (2012)

Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?
por: Contractor, Tahmeed, et al.
Publicado: (2011)

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2019)

Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

On-treatment follow-up in real-world studies of direct oral anticoagulants in atrial fibrillation: Association with treatment effects
por: Hutto, David, et al.
Publicado: (2022)

Effectiveness and safety of oral anticoagulant therapy in a real-world cohort with atrial fibrillation: The SIESTA-A study protocol
por: Montero-Balosa, M. C., et al.
Publicado: (2023)

Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective
por: Altman, Raul, et al.
Publicado: (2011)

Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort
por: Rodríguez-Bernal, Clara L., et al.
Publicado: (2017)

Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation: A PRISMA-compliant article
por: Kim, Seung Min, et al.
Publicado: (2021)

Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis
por: Shen, Nan-Nan, et al.
Publicado: (2021)

Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2022)

Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease
por: Undas, Anetta
Publicado: (2023)

Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants?
por: Annoni, Giorgio, et al.
Publicado: (2016)

Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation
por: Kwon, Chang Hee, et al.
Publicado: (2016)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

A Multilevel Analysis of Real-World Variations in Oral Anticoagulation Initiation for Atrial Fibrillation in Valencia, a European Region
por: García-Sempere, Aníbal, et al.
Publicado: (2017)

Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin
por: Pyykönen, Mikko, et al.
Publicado: (2021)

Effectiveness and Safety of Direct Oral Anticoagulants in Thai Patients with Atrial Fibrillation: A Real-World Retrospective Cohort Study
por: Srikajornlarp, Saowaluk, et al.
Publicado: (2022)

Efficacy and Safety of Antithrombotic Therapy With Oral Anticoagulants in Real-World Elderly Patients With Acute Coronary Syndrome and Atrial Fibrillation
por: Wu, Yangxun, et al.
Publicado: (2022)

Primary Nonadherence to Oral Anticoagulants in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort
por: Rodriguez-Bernal, Clara L., et al.
Publicado: (2018)

Real-world clinical outcomes of oral anticoagulants among Japanese patients with atrial fibrillation and concomitant coronary artery disease
por: Chen, Yijiao, et al.
Publicado: (2023)

Atrial fibrillation in older patients—reducing stroke risk is not only about anticoagulation
por: Win, Nay Thu, et al.
Publicado: (2016)

Survey Study of the Real‐World Outpatient Management of Postoperative Atrial Fibrillation
por: Patel, Nirav V., et al.
Publicado: (2023)

Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter
por: Fradley, Michael G., et al.
Publicado: (2020)

Prevalence of oral anticoagulation in atrial fibrillation
por: Bartholomay, Eduardo, et al.
Publicado: (2014)

Anticoagulation for atrial fibrillation in active cancer
por: Farmakis, Dimitrios, et al.
Publicado: (2022)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)

Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol
por: Holbrook, Anne, et al.
Publicado: (2016)

Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
por: Pham, Phuong N., et al.
Publicado: (2019)

Real-world adherence to oral anticoagulants in atrial fibrillation patients: a study protocol for a systematic review and meta-analysis
por: Rodríguez-Bernal, Clara L, et al.
Publicado: (2018)

Real‐world use of nonvitamin K antagonist oral anticoagulant in atrial fibrillation patients with liver disease: A meta‐analysis
por: Dai, Qixin, et al.
Publicado: (2020)

Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data
por: Moret, Carla, et al.
Publicado: (2023)

Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world
por: Kozieł, Monika, et al.
Publicado: (2021)

Anticoagulation in Cancer Patients With Atrial Fibrillation or Atrial Flutter: Are There Gaps in Care?
por: Russo, Andrea M.
Publicado: (2020)

Veterans Perceptions of Satisfaction and Convenience with Anticoagulants for Atrial Fibrillation: Warfarin versus Direct Oral Anticoagulants
por: Mull, Hillary J, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_btokpk4jr90cpc1u982r4l7ukb